INTRODUCTION
Meningococcal meningitis is a serious public health problem, especially in the part of sub-Saharan Africa called the meningitis belt of Lapeyssonnie. This area stretches from Senegal to Ethiopia and has an estimated population about 500 million people. This belt has become a ramp that includes other African countries (1) . Every year, an upsurge in cases of meningitis occurs during the dry season in countries located in this area, which thus have a high endemic background (1, 2, 3) .
According to the World Health Organization (WHO), there have been 700,000 cases of meningococcal meningitis globally over the last 15 years,with an estimated lethality rate of more than 10% and a considerable proportion of sequelae, sometimes reaching 20%(4).
During epidemics, about 90% of cases are attributable to Neisseria meningitides serogroup A, W, X (3). Since records began, meningococcal serogroup A has been the dominant cause of epidemics of meningococcal meningitis in this region; however, NmW and NmX have also been responsible for epidemics (5, 6, 7, 8) .
Burkina Faso, a landlocked West African country with a population of roughly 18 million, is one of the few countries entirely located within the meningitis belt and has hyperendemic rates of meningitis (3, 9, 10) . From 2003 to 2009, there were 78,518 reported cases of meningococcal meningitis with 8,568 deaths (11%) in Burkina Faso. Among the fatal cases, 5.569 (65%) were caused by group A N. meningitides (11).
From 2010 to 2012, NmX has been responsible for meningitis epidemics in Burkina Faso, causing 59% of the confirmed cases of meningococcal meningitis in this country in 2011 (12) .The lethality rates of meningitis caused by this serogroup were as high as those reported for NmA (12) ; children aged 1-9 years being the most frequently affected age group (12) .
The mechanisms leading to the spread of infections linked to meningococcal infections and to epidemics of meningococcal meningitis remain unknown. The rate of asymptomatic carriage may reach 15% in Africa during epidemics (13, 14, 15). The environmental conditions present in the meningitis belt of sub-Saharan Africa during the dry season, particularly the high temperatures, very low humidity, and the Harmattan (dusty wind that blows from the Sahara), and respiratory coinfections related to degradation of mucosal barriers defenses are considered to contribute to the increase in sensitivity to meningococcal disease (16, 17, 18, 19) . Several studies have shown the importance of the dynamics of asymptomatic carriage in individuals and communities and the effect of the season on colonization by meningococci (20, 21, 22, 23) .
Over the past three decades, control of meningitis epidemics in the African meningitis belt has been confined to reactive vaccination with polysaccharide vaccine when the incidence in a given administrative area has reached a critical incidence (4) . Implementing reactive vaccination with polysaccharide vaccine at the beginning of an epidemic has saved many lives; however, it does not decrease the frequency of outbreaks because polysaccharide vaccines confer protection for a limited time, especially in children, and have little or no impact on asymptomatic carriage (20) . Conjugate vaccines, in which polysaccharidesare linked to a supportprotein, are likely to be more effective in preventing epidemics because they induce immunological memory and decrease pharyngeal carriage (21) .
As a prelude to the introduction of the conjugate vaccine A, Burkina Faso initiated a study of nasopharyngeal carriage of meningococcus in three health districts (Bogodogo, Dandé, and Kaya). After the introduction of immunization, other carriage studies have been conducted, mainly to evaluatethe impact of the vaccine on serogroup A and on the carriage of the other two main N. meningitides serogroups: X and W.
In December 2010, the meningococcal A vaccine, MenAfriVac, was introduced in Burkina Faso through a mass vaccination program aimed at reducing the frequency of occurrence of cases and outbreaks related to serogroup A, which is the usual causative agent in the African cerebrospinal meningitis belt. Considering the results obtained elsewhere byadministering anti-meningococcal conjugate vaccines (24, 25, 26) , MenAfriVacwas expected to impact the rate of both carriage and the occurrence of meningitis due to NmA in Burkina.
The aim of this study was to evaluate the impact of conjugate vaccine A, MenAfriVac, on the frequency of occurrence of clinical cases of cerebrospinal meningitides and NmA carriage, and possibly cases associated with other common serogroups in Burkina Faso. 
MATERIALS AND METHODS

Ethical
Considerations
Study
Sites The study was conducted in three health districts of Burkina Faso (Bogodogo, Kaya, and Dandé). Villages or sectors in each district were chosen randomly. In BogodogoDistrict, an urban district located in the capital of Burkina Faso, oropharyngeal samples and cerebrospinal fluid wereprocessed by the laboratory of Charles De Gaulle pediatric hospital. In Kaya District, which is a rural district located in north-eastern Burkina Faso, samples were sent to and processed by the laboratory of the Regional Hospital of Kaya (CHR) and the bacteriology laboratory of the university teaching hospital of Yalgado Ouedraogo. Finally, in the rural district of Dandé, which is located in the western part of the country, the Bacteriology Laboratory of the university teaching Hospital of Bobo Dioulasso, Souro Sanou Hospital, was in charge of bacteriological analysis of samples.
Type and period of the study
This descriptive cross-sectionalstudy was performed foranalytical purposes and comprisedfive separate rounds 3 monthsbefore and after vaccination. The study was conducted from January 2009 to November 2011.During this period, specimens were collected to obtain data on asymptomatic carriage of N. meningitidis. However, data related to cerebrospinal meningitis cases was collected continuously between 2009 and2013 in the three health districts studied.
Sampling for meningococcal carriage
A sample representing persons aged 1 to 29 years was obtained by cluster sampling at several levels as follows: Eight villages were selected randomly in each of the two rural districts studied (Dandé and Kaya). For each campaign, 42 concessions per village were selected by simple random sampling from maps showing the Global Positioning System (GPS) coordinates of all concessions in the selected villages, these maps having been prepared before the start of the study. All persons in the target group who lived in one of the randomly selected concessionswere invited to participate in the study.
In the urban district studied (Bogodogo), all residential blocks were identified on a geographical map of the district. Sixteen blocks per campaign were selected by simple random sampling and mapped with GPS coordinates. During each campaign, all households in the selected blocks were visited and eligible subjects invited to participate in the study.
Sampling for cases of cerebrospinal meningitis
The sample of cases of cerebrospinal meningitis comprised all cases registered in the Ministry of Health database (National Epidemiological Surveillance System) during the period of the study.The cases of cerebrospinal meningitisin the three health districts studied (Bogodogo, Dandé, and Kaya) were selected according to the WHO definition of acute bacterial meningitis, which classifies cases as 'suspected'or'laboratoryconfirmed'.
Data collection for meningococcal carriage
The residents of the study sites were first informed of the project by local health workers and community leaders. Each randomly selected household was visited by the study staff and questionnaires administered to all target family members after they had signed individual writteninformed consent forms. The consent of a parent or guardian was obtained for children aged less than 18 years. Oropharyngeal specimens were obtained by swabbing the posterior wall of the pharynx with a sterile cotton swab, these samples being collected by technicians who had previously been trained to take such swabs.Each participant received a paper bracelet with a bar code corresponding to a unique identification number linked to the questionnaire.
Data collectionfor cases of meningococcal meningitis
Data was collected on an especially designed form for each case. The primary tools for collecting these data were clinical records, recordsofnotification of cases, the documents that accompanied the samples, and results of laboratory analysis of cerebrospinal fluid (CSF).
RESULTS
Rate of carriage of meningococcus in the selected three health districts of Burkina Faso before the introduction of meningococcal A conjugate vaccine MenAfriVac
The overall carrier rate of serogroup Nm before vaccination was 2.84% (680/23885) ( Table I ). In the Bogodogo health district, the overall carriage rate was 1.08% (93/8596) and the carriage rates of NmA0.11%, of NmX0.32%, of NmY0.51%, and of NmW0.12%. In the Dandé health district, the overall carriage rate was 3.14% (270/8582) and the carriage rates of NmA0.18%, ofNmX0.27%, of NmY2.49%, and of NmW 0.20%. Finally, in the Kaya health district, the overall carriage rate was 4.72% (317/6707) and the carriage rates of NmA 0.83%, of NmX 0.79%, of NmY 2.81%, and of NmW 0.28%.
Notably, the prevalence of NmY (65.7%) prior to vaccination was 4-fold that ofNmX (15.3%), 5-fold that ofNmA (12.1%) and more than 9-fold greater than that ofNmW (6.9%)( Table II) (Table III) . 
DISCUSSION
Cerebrospinal meningitis is a major public health problem in countries of the meningitidis belt such as Burkina Faso. With the aim of reducing the negative impact of this disease, there havebeen vaccination campaigns in Burkina Faso and many other African countries that are subject to outbreaks of this disease.
TheMenAfriVac vaccine wasspecifically developed to targettheNmAserogroup. Prior to the vaccination campaign, the prevalence of asymptomatic carriage of this serogroup was 0.11% in the Bogodogo district, 0.18% in the Dandé district, and 0.83% in the Kaya district. Post-vaccination, a single NmA carrier was identified intheBogodogo district; this carrier had not received the MenAfriVac vaccine. Thus, this study showed that NmA carriage had almost total disappeared from the three study sites, confirming that the conjugate vaccine MenAfriVac greatly reduces the prevalence of NmA carriage (23, 27, 28, 29, 30). A study conducted in Brazil in 2010 also showed that the conjugate vaccine reduces the prevalence of rhinopharyngeal colonization by Nm However, post-vaccination, NmA was not isolated from the CSF of any patients with cerebrospinal meningitis in any if the studydistricts. This disappearance of NmA may be associated with the effect of the MenAfriVac conjugate vaccine on this serogroup. This finding is similar to those of several other studies (33, 34) .
Of note, we found an increase in prevalence of NmX carriage post-vaccination in the Bogodogo and Kaya districts, from 0.32% to 0.42% and from 0.79% to 10.17%, respectively. In contrast with patients with meningitis in Bogodogo, the prevalence of NmXwas higher in the CSF of patients with meningitis in the Kaya district post-vaccination, doubling from 16 to 32 cases compared with the pre-vaccination era. The particularly high prevalence of asymptomatic carriers of NmX in theBogodogo and Kaya districts and of laboratory-proven NmX cerebrospinal meningitis in theKaya health district could be related to the close proximity of these districts to Niger, where outbreaks caused by this serogrouphaveoccurred since 2006 (7, 35, 36) .
Also of note, the post-vaccination NmW carriage rate in the Dandé health district was 20-fold that before introduction of the vaccine (0.20% vs. 4.01%). Similarly, the post-vaccination prevalence of laboratory-confirmed NmW meningitis in this district was 9-foldthat found in the pre-vaccination era.This very significant presence of the NmW serogroup in the Dandé district post-vaccination is likely related to the proximity of this city to Mali,in which cases of laboratory-confirmed NmW meningitis were reported in 2007 and 2009 (34, 37) . A post-vaccination increase in the prevalence of asymptomatic carriers of NmWwas also seen in the health district of Bogodogo, the rate there increased from 0.12% to 0.58%. Also, whereas this serogroup had not been isolated from patients with meningitis in this district pre-vaccination, post-vaccination there were 16 such cases (17.58%). Of note, the capital of Burkina Faso (Ouagadougou), in which theBogodogo district is located, is a crossroads through which many people continuously move into the country for diverse reasons. The significant presence of the NmW serogroup in this town could be attributable to thisinflux of people, including some from areas to the west thathave borders withMali.
Studies by Paul and colleagues have shown that the NmW observed in Burkina Faso post-vaccination belong to the NmW clone ST-11, which hadlast been seen in the country in 2006 but reappeared after the MenAfriVac nationwide mass vaccination campaign (38) . This clone has been identified both in carriers of NmW non-invasive strains and in patients with meningitis (23, 34,39). Thus far, the ability of NmW to cause large epidemics has been associated with the hyper-virulent ST-11 clone (34, 40, 41, 42) . In our study, we identified persistence of the NmW serogroup in 2013 in patients in the Bogodogo and Dandé districts. This may imply that a new strain of hyper-virulent NmW emerged after the mass vaccination with MenAfriVac, which resulted in the disappearance of NmA carriers and patients with laboratory-confirmed NmA meningitis in the three studied health districts.
In general, we believe it is important to note that the unusual emergence of NmX and NmW serogroups post-vaccination was associated with the virtual absence of NmA. This finding is particularly relevant in light ofthe observed increase in overall prevalence of meningococcus after vaccination with MenAfriVac conjugate vaccine in the sites of our study among asymptomatic carriers (from 2.84% to 6.42%) and patients with meningitis (from 43.2% to 50.83%). Of note, there was also an increase in the global meningococcal carriage rate in the threestudied districts. Indeed, in the Bogodogo district it increased from 1.08% to 1.10%, in Dandéfrom 3.14% to 6.2%, and in Kaya from 4.72% to 11.08%. This increase in prevalence of asymptomatic carriers of meningococcuspostvaccination was linked with a very low rate of carriage of NmA. Paul et al. reported similar findings (43).
In contrast with these two serogroups, we identified a significant decrease in the rate of carriage of NmY within the three studied districts post-vaccination. The prevalence of this serogroup dropped from 0.51 % to 0.09% in Bogodogo, from 2.49% to 1.60% in Dandé, and from 2.81% to 0.52% in Kaya. This reduction may reflect the effects of group immunity, including immunity against NmA. Despite the very high prevalence of carriage of this serogroup in all the health districts, analysis of CSF from patients with meningitis in all three studied districts postvaccination revealed a single patient from whom NmYwas isolated, this patient being in the Bogodogo health district. Serogroup Y meningococcal meningitis does not appear to be associated with outbreaks, but rather occurs sporadically (44).
CONCLUSION
In this study, we identified the disappearance of both NmA carriage andserogroup A meningococcal meningitis since the introduction in Burkina Faso of the MenAfriVac anti meningococcal A conjugate vaccine in December 2010. Despite the introduction of this vaccine, Burkina Faso remains vulnerable to outbreaks related to serogroup X, for which no vaccine is currently available, and to re-emergence of serogroup W, because the prevalence of these two serogroups both in asymptomatic carriers and in patients with meningitis has increased postvaccination in the three studied health districts. It is therefore essential to review strategies against acute bacterial meningitis. Strengthening surveillance is essential to monitoring these changes, detectingepidemics in a timely manner and remaining reactive to those caused by any Nm serogroup.
